Thursday, November 14, 2024
HomeTagsCologuard

Cologuard

Exact Sciences Presents Colorectal Cancer Screening Solution for Patients

Exact Sciences Corp. (NASDAQ: EXAS) announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing overall sensitivity of 95.2% for colorectal cancer...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics